$8m · Series A · Cleantech · Oxford, UK
Oxford-based HydRegen, which develops enzyme-based catalysts for chemical manufacturers, has raised $8m (£6m) in the first close of its Series A. Genoa Ventures led the financing, with Clean Growth Fund and First Imagine! Ventures participating alongside Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital and Rapid Innovation Group. The company says the capital will deepen work with pharmaceutical and specialty-chemical customers and support expansion into agrochemicals, materials and bulk chemicals.
Hydrogenation is used across chemical manufacturing, but conventional processes often depend on precious-metal catalysts. HydRegen produces a hydrogenase enzyme through fermentation and formulates it into catalyst platforms intended to run many different hydrogenation reactions. Its pitch is deliberately practical: manufacturers can change the catalyst while continuing to use installed batch or continuous-flow equipment.
Changing the catalyst, not the factory
That compatibility is central to HydRegen's commercial model. A cleaner process is easier to adopt when a customer can test it inside familiar reactors instead of funding a new plant. HydRegen sells evaluation samples and moves successful projects into joint development, so the route to revenue depends on converting technical trials into repeatable manufacturing processes.
The company says its technology can make some processes up to 40% more cost-effective while lowering emissions. Those figures are company claims and will vary by molecule and operating conditions. The more durable advantage, if trials support it, is the ability to spread one enzyme-production system across multiple reactions: fermentation costs can be shared across a broader product portfolio instead of being tied to a single chemical.
From kilo-lab evidence to higher-volume markets
HydRegen has already completed a kilo-lab demonstration with Almac Sciences using its H2BioCat platform and an Almac enzyme. The partners reported more than 99.9% conversion in an industrially relevant timeframe, under mild pressure and temperature. That is a scale-up milestone, not evidence of sustained commercial production, but it gives prospective customers a more concrete reference point than bench-scale chemistry alone.
The Series A will test whether HydRegen can turn that technical progress into repeatable adoption. Moving from pharmaceutical and specialty-chemical projects into agrochemicals and bulk chemicals increases the potential volume, while raising the bar on price, catalyst lifetime and dependable process transfer. Genoa Ventures framed its investment around capital efficiency and the company's attempt to fit biology into the economics and infrastructure of existing plants. The next proof point is not another laboratory result; it is whether customer evaluations become licensed or recurring manufacturing deployments.
